This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
14 Mar 2012

DSM & Agennix Sign New Contract for Talactoferrin

DSM Pharmaceutical Products and Agennix AG have signed a new contract under which DSM will manufacture the oral Dendritic Cell Mediated Immunotherapy talactoferrin for Agennix at commercial levels.

DSM Pharmaceutical Products and Agennix AG have inked a new agreement under which DSM will continue to provide commercial manufacture of talactoferrin for Agennix.

 

DSM is currently manufacturing talactoferrin for ongoing clinical trials and will continue to supply clinical trials as well as a potential commercial launch.

 

Under the contract, DSM will manufacture the oral Dendritic Cell Mediated Immunotherapy (DCMI) talactoferrin at commercial levels in anticipation of positive Phase III results and product approval. The contract includes the opportunity to expand production capacity as needed.

 

Rajesh

Related News